Generics Growth Strategies

Cost Containment and M&A Shape The Global Generics Industry

Publication Date	September 2009
Publisher	Business Insights
Product Type	Report
Pages	129
ISBN Number	not applicable
Product Code	RBI00312

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

FAX Order above formats by FAX

Summary

The last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the level of deals has declined due to the implications of restricted debt markets and the need to reduce company debt. The global financial crisis has also affected government debt and subsequently healthcare cost containment has become a prominent issue. Many nations and in particular the US is seeking to reduce healthcare costs through promotion of generics and creating better approval pathways for biogenerics. This report analyzes both quantitatively and qualitatively the unbranded generics industry, the top 10 generics companies by unbranded generics sales, the top 5 therapy areas and the major North American, European, Asia Pacific and Latin American markets. This report also identifies key trends in M&A strategies including case studies of major M&A deals from 2005 onwards.

Content

Executive summary
- Generics growth drivers and resistors
- Consolidation within the generics industry
- The generics industry by country and region
- Therapy area analysis
- Leading generics pharma companies
Chapter 1 Generics growth drivers and resistors
- Summary
- Introduction
- Growth drivers for generics
- Company growth opportunities
- Growth through paragraph IV challenges
- Generic biologics
- Mergers and acquisitions
- External factors influencing generics growth
- Healthcare cost containment
- Improving drug approval pathways
- Improving the biosimilars approval pathway
- Threats to the generics industry
- Patent litigation
- Reformulation
- DTC and Rx to OTC switching
- Authorized generics and in-house generics
Chapter 2 Consolidation within the generics industry
- Summary
- Introduction
- M&A strategies
- Manufacturing facilities
- Economies of scale
- Generic biologics
- Therapeutic expansion
- Drug technology access
- Geographic expansion and diversification
- Selected M&A deals
- Actavis
- Acquisition of Alpharma
- Acquisition of Amide
- Acquisition of Sindan
- Acquisition of Keri Pharma
- Apotex
- Acquisition of Lareq
- Acquisition of Topgen
- Daiichi Sankyo
- Acquisition of Ranbaxy
- Dr. Reddy's
- Acquisition of Betapharm
- Acquisition of Roche's API facility
- Acquisition of Trigenesys
- Hospira
- Acquisition of Mayne Pharma
- Mylan
- Acquisition of Matrix Laboratories
- Acquisition of Merck KGaA's generics business
- Novartis (Sandoz)
- Acquisition of Sabex
- Acquisition of Hexal and Eon
- Ratiopharm
- Acquisition of Magnafarma
- Acquisition of Pulmotec and Ribosepharm
- Sanofi-Aventis (Winthrop)
- Acquisition of Zentiva
- Acquisition of Laboratorios Kendrick
- Stada
- Acquisition of Hemofarm
- Acquisition of Nizopharm
- Other acquisitions
- Teva
- Acquisition of Barr
- Acquisition of Ivax
- Watson
- Acquisition of Arrow
- Acquisition of Amarin
- Acquisition of Sekhsaria
- Acquisition of Andrx
- Conclusion
Chapter 3 The generics industry by country and region
- Summary
- Introduction
- North America
- Five major European markets
- Central and Eastern Europe
- AsiaPac
- Japan
- China
- Other selected AsiaPac markets
- Latin America
Chapter 4 Therapeutic analysis of the generics industry
- Summary
- Introduction
- CNS market
- Leading generics companies by sales
- Top selling molecules
- Cardiovascular market
- Leading generics companies by sales
- Top selling molecules
- Anti-infectives market
- Leading generics companies by sales
- Top selling molecules
- Alimentary tract and metabolism market
- Leading generics companies by sales
- Top selling molecules
- Oncology market
- Leading generics companies by sales
- Top selling molecules
Chapter 5 Leading generics companies
- Summary
- Introduction
- Sales analysis of key generics players
- Unbranded generics sales
- Branded and unbranded focus
- Regional analysis of leading generics players
- Company portfolio and strategic analysis
- Teva
- Selected news & events
- Mylan
- Selected news & events
- Novartis (Sandoz)
- Selected news & events
- Ratiopharm
- Selected news & events
- Watson
- Selected news & events
- Stada
- Selected news & events
- Hospira
- Selected news & events
- Apotex
- Selected news & events
- Servier
- Pfizer (Greenstone)
- Selected news & events
- Future Outlook
- Cost containment
- Outperforming branded pharmaceuticals
- Biogenerics/Biosimilars
- Loss of price advantage and low cost manufacturers
Chapter 6 Appendix
- Primary research methodology
- Glossary
- Index
List of Figures
- Figure 1.1: Growth opportunities and threats for generics companies
- Figure 1.2: Average number per month of original and total ANDA approvals by the FDA, 2001 ??